IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112424 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Jianbo Shen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, Jiangsu, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Epithelial Cell Adhesion Molecule, CD3 Complex. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Colorectal cancer is a major global health burden, with limited efficacy of traditional treatment modalities in improving survival rates. However, recently advances in immunotherapy has improved treatment outcomes for patients with this cancer. To address the continuing need for improved treatment efficacy, this study introduced a novel tri-specific antibody, IMT030122, that targets EpCAM, 4-1BB, and CD3. We evaluated the pharmacological efficacy and mechanism of action of IMT030122 in vitro and in vivo. In in vitro studies, IMT030122 exhibited differential binding to antigens and cells expressing EpCAM, 4-1BB, and CD3. Moreover, IMT030122 relied on EpCAM-targeted activation of intracellular CD3 and 4-1BB signaling and mediated T cell cytotoxicity specific to HCT116 colorectal cancer cells. In vivo, IMT030122 demonstrated potent anti-tumor activity, significantly inhibiting the growth of colon cancer HCT116 and MC38-hEpCAM subcutaneous grafts. Further pharmacological analysis revealed that IMT030122 recruited lymphocytes from peripheral blood into colorectal cancer tissue and exerted durable anti-tumor activity, predominantly by promoting the activation, proliferation, and differentiation of CD8T cells. Notably, IMT030122 still exhibited anti-tumor efficacy even in the presence of significantly depleted lymphocytes in colorectal cancer tissue. The potent pharmacological activity and anti-tumor effects of IMT030122 suggest it may enhance treatment efficacy and substantially extend the survival of patients with colorectal cancer in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, Jiangsu, China.
- Beijing Immunoah Pharma Tech Co., Ltd., Beijing 100141, China.
- Department of Preventive Treatment of Disease, Chengde Traditional Medicine Hospital, Hebei 067000, China.
- Department of Gastroenterology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China.
- Department of Gastroenterology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China. Electronic address: zhougx@ntu.edu.cn.
- Beijing Immunoah Pharma Tech Co., Ltd., Beijing 100141, China. Electronic address: xuqinzhi@immunoah.cn.
Zitieren
APA
Shen, J., Qian, N., Xu, G., Dou, X., An, Y., Yang, C., Liu, Y., Liu, Y., Pan, X., Wang, J., Bai, G., Chen, H., Zhu, X., Gao, X., Zhou, G., & Xu, Q. (2024). IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112424
Vancouver
Shen J, Qian N, Xu G, Dou X, An Y, Yang C, et al. IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112424
BibTeX
@article{Shen2024,
author = {Shen, Jianbo and Qian, Niliang and Xu, Guili and Dou, Xiaoqian and An, Ying and Yang, Cuima and Liu, Yujie and Liu, Yunhui and Pan, Xiujie and Wang, Jingjing and Bai, Guijun and Chen, Hao and Zhu, Xiaolin and Gao, Xin and Zhou, Guoxiong and Xu, Qinzhi},
title = {IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112424}
}
EUVIMED